Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Sesen Bio Inc (SESN)

Sesen Bio Inc (SESN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 140,263
  • Shares Outstanding, K 199,464
  • Annual Sales, $ 26,540 K
  • Annual Income, $ -340 K
  • 60-Month Beta 0.59
  • Price/Sales 5.30
  • Price/Cash Flow 8.82
  • Price/Book 0.99
Trade SESN with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.07
  • Most Recent Earnings -0.05 on 08/08/22
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 159.66% ( -16.33%)
  • Historical Volatility 132.25%
  • IV Percentile 52%
  • IV Rank 13.55%
  • IV High 640.08% on 06/15/22
  • IV Low 84.39% on 12/23/21
  • Put/Call Vol Ratio 1.49
  • Today's Volume 553
  • Volume Avg (30-Day) 782
  • Put/Call OI Ratio 0.37
  • Today's Open Interest 76,538
  • Open Int (30-Day) 75,292

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.09
  • Number of Estimates 2
  • High Estimate -0.05
  • Low Estimate -0.12
  • Prior Year -0.02
  • Growth Rate Est. (year over year) -350.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6005 +17.24%
on 07/19/22
0.9650 -27.05%
on 07/14/22
-0.1460 (-17.18%)
since 07/11/22
3-Month
0.3940 +78.68%
on 05/12/22
0.9650 -27.05%
on 07/14/22
+0.2939 (+71.67%)
since 05/11/22
52-Week
0.3650 +92.88%
on 05/02/22
6.0400 -88.34%
on 08/13/21
-3.3360 (-82.57%)
since 08/11/21

Most Recent Stories

More News
Epizyme (EPZM) Q2 Earnings Beat Estimates, Revenues Up Y/Y

Epizyme (EPZM) posts a narrower-than-expected loss in the second quarter. Revenues beat estimates.

NVAX : 40.34 (-2.47%)
EPZM : 1.4700 (-1.34%)
IPSEY : 26.0800 (+3.66%)
SESN : 0.7040 (+0.11%)
Reata (RETA) Q2 Earnings Miss, Revenues Down Y/Y, Stock Down

Reata (RETA) reports a wider-than-expected loss in the second quarter of 2022, while revenues miss estimates. Stock falls after updates on pipeline programs.

NVAX : 40.34 (-2.47%)
ABBV : 142.08 (+0.81%)
RETA : 20.96 (-2.78%)
SESN : 0.7040 (+0.11%)
Puma Biotech (PBYI) Stock up as Q2 Earnings & Sales Beat

Puma Biotech (PBYI) beats earnings and revenue estimates in second-quarter 2022. PBYI's stock surges at market close following the news.

RHHBY : 41.0400 (-2.49%)
NVAX : 40.34 (-2.47%)
PBYI : 3.55 (-0.56%)
SESN : 0.7040 (+0.11%)
Biohaven Pharmaceutical (BHVN) Q2 Earnings Lag, Sales Beat

Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine, continues to demonstrate strong demand in the United States. BHVN also reports a wider-than-expected Q2 loss.

PFE : 48.29 (-3.32%)
NVAX : 40.34 (-2.47%)
BHVN : 147.61 (+0.34%)
SESN : 0.7040 (+0.11%)
Sesen Bio Reports Second Quarter 2022 Financial Results and Business Update

Sesen Bio (Nasdaq: SESN ) today reported operating results for the second quarter ended June 30, 2022. During the quarter, the Company paused clinical development of its lead asset, Vicineum™ for the...

SESN : 0.7040 (+0.11%)
What's in the Cards for Sesen Bio's (SESN) Q2 Earnings?

Sesen Bio's (SESN) Q2 performance is likely to reflect cost savings from the company's restructuring plans as the company continues to seek a potential partner for the further development of Vicineum.

RGEN : 246.49 (-3.79%)
BGNE : 196.64 (+2.75%)
SESN : 0.7040 (+0.11%)
BNTX : 158.59 (-1.45%)
Sesen (SESN) Halts Bladder Cancer Drug Development, Stock Down

Sesen Bio (SESN) decides to pause the development of Vicineum in the United States. It also ended its 2016 licensing agreement with Roche in exchange for an upfront payment of $40 million.

RHHBY : 41.0400 (-2.49%)
SGEN : 174.04 (-0.92%)
SESN : 0.7040 (+0.11%)
BNTX : 158.59 (-1.45%)
Sesen Bio Announces Strategic Decision to Pause Clinical Development of Vicineum™ in the US

Sesen Bio (Nasdaq: SESN ) today announced that it has made the strategic decision to voluntarily pause further development in the US of its lead asset, Vicineum. The decision was based on a thorough...

SESN : 0.7040 (+0.11%)
VERU's Shares Jump on Successful COVID-19 Study Results

VERU gains on the success of its late stage study evaluating the efficacy and safety of oral sabizabulin 9 mg for COVID-19.

GERN : 2.05 (-5.53%)
GILD : 62.45 (-1.09%)
VERU : 16.01 (+36.02%)
SESN : 0.7040 (+0.11%)
Chinook (KDNY) Stock Rallies 24.2% in 3 Months: Here's Why

Despite no marketable drugs in its portfolio, Chinook (KDNY) is progressing well with its pipeline. Updated data from a study supports the potential clinical utility of BION-1301 in the IgA nephropathy...

NVO : 108.79 (+1.19%)
ABBV : 142.08 (+0.81%)
SESN : 0.7040 (+0.11%)
KDNY : 19.99 (-2.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Sesen Bio Inc. is a late-stage company developing next-generation antibody-drug conjugate therapies for patients with cancer. The company's product portfolio includes Vicinium(TM) which is in its clinical trial, treats high-grade non-muscle invasive bladder cancer. Sesen Bio Inc., formerly known as Eleven...

See More

Key Turning Points

3rd Resistance Point 0.7915
2nd Resistance Point 0.7692
1st Resistance Point 0.7366
Last Price 0.7040
1st Support Level 0.6817
2nd Support Level 0.6594
3rd Support Level 0.6268

See More

52-Week High 6.0400
Fibonacci 61.8% 3.8721
Fibonacci 50% 3.2025
Fibonacci 38.2% 2.5329
Last Price 0.7040
52-Week Low 0.3650

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar